Posts tagged Christopher James
Ladenburg ups Intra-Cellular to buy

Ladenburg Thalmann upgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “buy” from “neutral” with a $36 price target, reflecting a positive update from the FDA about the company’s schizophrenia program. The stock closed at $15.90 on August 29.

Read More
Ladenburg starts Bellerophon at buy

Ladenburg Thalmann initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.18 on April 13.

Read More